Suven Life Sciences Reports Positive Phase 2b Depression Trial Results

Suven Life Sciences announced positive Phase-2b results for Ropanicant in treating Major Depressive Disorder, meeting the primary endpoint with a -3.572 MADRS score difference versus placebo (p=0.038). Management is planning a global Phase-3 registrational study. The drug was generally well-tolerated with no safety signals identified.